MR imaging helps predict recurrence in prostate cancer patients

NewsGuard 100/100 Score

MR images taken of prostate cancer patients prior to treatment that show that the cancer has spread outside the prostate gland capsule help predict whether the cancer will return, according to a recent study conducted by radiologists at the University of California-San Francisco.

The study consisted of 74 men with biopsy-proven prostate cancer who underwent endorectal MR imaging of the prostate, said Antonio Westphalen, MD, lead author of the study. Tumor size, stage and extracapsular extension (cancer spread outside the prostate gland capsule) were all recorded.

"The study focused on patients who were treated with radiation therapy, more specifically, external beam radiation therapy, which is the treatment of choice of about one-third of patients with newly diagnosed prostate cancer," said Dr. Westphalen.

After a follow-up of an average 42 months, four patients developed metastases , all four had extracapsular extension seen on MR imaging before treatment, Dr. Westphalen said. Three of them had more than 5mm of extracapsular extension at MR imaging, he said.

"The main goal of our study was to identify features on our imaging that would predict treatment failure, perhaps allowing for a more conscientious decision ahead of time. We found that a subset of patients who presented with imaging signs of extracapsular extension prior to radiation were more likely to develop metastases in the future," said Dr. Westphalen.

The full results of the study wer presented during the American Roentgen Ray Society Annual Meeting in Orlando, FL.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis